Placebo
DrugOne tablet vaginal inserted at 4 hrly interval with maximum of three doses
NCT Number: NCT01428037
The purpose of this study is to estimate the efficacy and safety of the 25mcg vaginal misoprostol for cervical ripening and induction of labour.
Looking for future studies?
Notify Me20 year and older
Female
Interventional
Phase 3
The First Affliated Hospital with Nanjing Meical Uniersity, Nanjing, Jiangsu, China
There are many pregnant women require medical intervention to induce labor for some reasons at term. There are two fundamental changes that characterize pre-labor preparation for delivery: sensitization of the myometrium to produce contractions, and ripening (softening and dilation) of the cervix. A synthetic Prostaglandin misoprostol is fundamental to both of these changes. Low dose misoprostol is effective and safe for labor induction and has been used widely.
Oral tablets(200mcg) are broken into fragments and used intravaginally to ripen the cervix and induce labor due to the disadvantages of existing cervical ripeners (delivery of bolus doses, freezer or refrigerated storage, lack of efficacy in labor induction), and due to safety concerns with the off-label use of oral misoprostol tablet fragments, Regenex Corporation has developed a vaginal tablet with 25mcg misoprostol.
The primary objective of the study was to assess of the efficacy and safety of low dose (25 mcg) of misoprostol vaginal tablet for cervical ripening and induction of labour.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
One tablet vaginal inserted at 4 hrly interval with maximum of three doses
One tablet vaginal insert at 4 hrly interval with maximum of three doses
Other names: Misoprostol vaginal Tablet
Time frame: From the first dose to 12-24 hours
Treatment success is defined as: ≧3 of Bishop score increased within 12 hours or Vaginal delivery within 24 hours.
Time frame: From the first dose to 24 hours
Time frame: From the first dose to labor onset
Time frame: From the first dose to neonate delivery
Time frame: From the first dose to neonate delivery
Regenex Pharmaceutical, China
Other
A Randomized,Double-blind,Placebo-controlled, Multicenter Study of the Efficacy and Safety of Vaginal Misoprostol for Cervical Ripening and Induction of Labor
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05864326
Cervical Ripening, Induction of Labor
Geneva, Canton of Geneva, Switzerland
View Trial DetailsNCT03138252
Cervical Ripening, Induction of Labor
Cleveland, Ohio, United States
View Trial DetailsNCT03111316
Cervical Ripening, Induction of Labor
Oklahoma City, Oklahoma, United States
View Trial DetailsNCT01127581
Cervical Ripening, Induction of Labor
Phoenix, Arizona, United States
View Trial Details